(Q34734267)

4 August 2017

1 reference

title

Temozolomide: a novel oral alkylating agent (English)

1 reference

4 August 2017

0 references

S J Danson

1

1 reference

4 August 2017

M R Middleton

series ordinal

2

1 reference

4 August 2017

publication date

1 June 2001

1 reference

Expert Review of Anticancer Therapy

4 August 2017

published in

1 reference

4 August 2017

volume

1

1 reference

4 August 2017

issue

1

1 reference

4 August 2017

page(s)

13-19

1 reference

Temozolomide, a novel alkylating agent with activity in the central nervous system, may improve the treatment of advanced metastatic melanoma

4 August 2017

cites work

1 reference

https://api.crossref.org/works/10.1586%2F14737140.1.1.13

Multicentre CRC phase II trial of temozolomide in recurrent or progressive high-grade glioma.

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737140.1.1.13

Meta-analysis of radiation therapy with and without adjuvant chemotherapy for malignant gliomas in adults

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737140.1.1.13

Inactivation of O6-alkylguanine-DNA alkyltransferase in human peripheral blood mononuclear cells by temozolomide.

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737140.1.1.13

Pharmacokinetic assessment of novel anti-cancer drugs using spectral analysis and positron emission tomography: a feasibility study.

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737140.1.1.13

Phase II trial of temozolomide in low-grade non-Hodgkin's lymphoma.

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737140.1.1.13

A phase II study of temozolomide in hormone-refractory prostate cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737140.1.1.13

A phase II study of temozolomide in advanced untreated pancreatic cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737140.1.1.13

Temozolomide in adult patients with advanced soft tissue sarcoma: a phase II study of the EORTC Soft Tissue and Bone Sarcoma Group

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737140.1.1.13

21 January 2018

Identifiers

DOI

10.1586/14737140.1.1.13

1 reference

4 August 2017

1 reference